| 摘要 |
Extracorporeal membrance oxygenation (ECMO) was originally used for neonatal pulmonary diseases, and in fact, it was really successful in this respect. However, when ECMO was extended to treat other diseases like acute respiratory failure, the result was disappointing. With the new development of nitric oxide inhalation, surfactant therapy, high frequency ventilation, liquid ventilation, and so on, the frequency of treatment with ECMO for neonatal pulmonary diseases is decreasing. On the other hand, with the new development of a microporous membrane oxygenator, heparin-bound surface, centrifugal pump, and better cannular design, ECMO resurged as a promising mode of treatment for patients requiring temporary cardiopulmonary support. |
